Actively Recruiting
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Led by University of Miami · Updated on 2026-02-23
33
Participants Needed
3
Research Sites
365 weeks
Total Duration
On this page
Sponsors
U
University of Miami
Lead Sponsor
K
Karyopharm Therapeutics Inc
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
CONDITIONS
Official Title
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with multiple myeloma according to International Myeloma Working Group criteria
- Bone marrow biopsy confirming t(11;14) translocation by certified lab test
- Relapsed or refractory multiple myeloma after at least two prior therapies
- Refractory to, ineligible for, or intolerant of at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD38 antibody
- Measurable disease by IMWG guidelines within 4 weeks before registration
- Age 18 years or older at time of consent
- ECOG performance status of 3 or less
- Adequate organ function shown by lab tests within 4 weeks before treatment
- Negative pregnancy test for women of childbearing potential
- Use of effective contraception during study and for 90 days after last dose
- Able and willing to provide written informed consent
You will not qualify if you...
- Previous treatment with selinexor or another nuclear export inhibitor
- Any active medical condition likely to interfere with study procedures
- Uncontrolled active infection needing intravenous antibiotics, antivirals, or antifungals within 1 week before treatment
- Known intolerance or allergy to glucocorticoids
- Pregnant or breastfeeding women
- Unstable heart conditions including symptomatic ischemia, severe heart failure, or recent heart attack
- Active hepatitis B without adequate antiviral therapy or uncontrolled hepatitis C
- Active gastrointestinal problems affecting swallowing or absorption of tablets
- Unable or unwilling to take recommended supportive medications for nausea or anorexia
- Serious psychiatric or medical conditions that could affect treatment or consent
- Contraindications to required concomitant drugs
- Inability or unwillingness to comply with study protocol or cooperate with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of Miami, Lennar Foundation Medical Center
Coral Gables, Florida, United States, 33146
Actively Recruiting
2
University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States, 33442
Actively Recruiting
3
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
Actively Recruiting
Research Team
A
Alanna Vossen
CONTACT
D
Dickran Kazandjian, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here